Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults
Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-grade Lymphoma in Adults
The study evaluates the efficacy and tolerability of alternating short cycles of high-dose
 and conventional chemotherapy in combination with rituximab in CD20 positive patients,
 followed by local radiation therapy in the case of initial mediastinal or central nervous
 system (CNS) involvement or a residual tumor after chemotherapy. A dose-reduced regimen is
 offered for patients estimated to be over 55 years, biologically.
Inclusion Criteria:

 -  Burkitt's leukemia or Burkitt's lymphoma or primary mediastinal large B-cell lymphoma
 or B-precursor lymphoblastic lymphoma or large cell anaplastic lymphoma

 -  Age > 15 years

 -  Written informed consent

 Exclusion Criteria:

 -  Serious secondary diseases, including psychiatric conditions, under which the required
 therapy compliance is not to be expected

 -  HIV infection

 -  Secondary lymphoma following prior chemotherapy/radiotherapy or active second
 malignancy

 -  Known severe allergy to foreign proteins

 -  Pre-treatment other than 1 cycle CHOP or similar; < 1 week of another chemotherapy.

 -  Pregnancy or nursing

 -  Participation in other studies that interfere with study therapy